deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 -420 [-2369; 1528] /10000
21/49 vs. 24/51
-1257 [-2605; 92] /10000
39/49 vs. 47/51
-